EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Enorama Pharma AB's Enterprise Value is kr12.46 Mil.
Enorama Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-46.09 Mil. Therefore, Enorama Pharma AB's EV-to-FCF for today is -0.27.
The historical rank and industry rank for Enorama Pharma AB's EV-to-FCF or its related term are showing as below:
OSTO:ERMA'
s EV-to-FCF Range Over the Past 10 Years
Min: -77.08 Med: -5.31 Max: -0.03
Current: -0.34
During the past 12 years, the highest EV-to-FCF of Enorama Pharma AB was -0.03. The lowest was -77.08. And the median was -5.31.
OSTO:ERMA's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.765
vs OSTO:ERMA: -0.34
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Enorama Pharma AB (OSTO:ERMA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Enorama Pharma AB's PE Ratio (TTM) for today is calculated as:
Enorama Pharma AB's share price for today is kr0.255.
Enorama Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Enorama Pharma AB EV-to-FCF Related Terms
Enorama Pharma AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ERMA vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's EV-to-FCF falls into.
Enorama Pharma AB's current Enterprise Value is kr12.46 Mil.
Enorama Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-46.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enorama Pharma AB (OSTO:ERMA) has a EV-to-FCF of -0.27 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Enorama Pharma AB and its competitors. According to the industry distribution chart, Enorama Pharma AB ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Enorama Pharma AB's EV-to-FCF too high?
Enorama Pharma AB's current EV-to-FCF is -0.27. Based on the distribution chart, Enorama Pharma AB ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #999999 out of 562 companies for EV-to-FCF. This places Enorama Pharma AB in the lower half of its industry. The industry median EV-to-FCF is 20.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.77, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current EV-to-FCF is -0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.26 — trading 37.8% below its estimated fair value. The current EV-to-FCF is -0.27. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current EV-to-FCF is -0.27 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.26 is trading 37.8% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Possible Value Trap.
Key valuation signals for OSTO:ERMA:
EV-to-FCF: -0.27
GF Value™: kr0.41 vs. price of kr0.26 (37.8% below fair value)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score
Get the complete analysis for OSTO:ERMA
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
